3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio These three healthcare stocks provide stability, relatively high dividend yields, and consistent growth.
Johnson & Johnson Likely To Report Higher Q2 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call JNJ will release its Q2 earnings on July 15, with analysts expecting earnings of $2.85 per share and revenue of $25.05 billion. Stock rose 3.6%.
Bristol Myers Squibb vs. Johnson & Johnson: Which Healthcare Stock Is a Better Buy in 2026? Bristol Myers Squibb trades at a deep discount, while Johnson & Johnson boasts higher margins and a broader reach. How do their financials and risks stack up?
These 3 Dividend Stocks Could Boost Your Income This July Realty Income, Johnson & Johnson, and Chevron offer yields ranging from 2.2% to 5.1% in July 2026, supported by analyst buy ratings and institutional accumulation.
This Vanguard ETF Is Built for a Market That's Finally Rotating Away From Big Tech As the megacap tech trade sputters, one attractive fund already owns what's leading instead -- and it's beating the market this year.
3 No-Brainer Dividend Stocks to Buy Right Now AbbVie, J&J, and Pfizer are all reliable income plays in this choppy market.
